To test this hypothesis, we employed intranasal OXT administration as an experimental intervention to evaluate the therapeutic potential for reversing SI‐induced AD‐related behavioral pathologies and to delineate the underlying neurobiological mechanisms. Here, OXT is linked to Alzheimer disease.